There are various types of SCH including SCH-A, B, or C. In a study 474 where mice were divided into six groups (control, model, 5-ASA, and SCH at varying doses), SCH-treated mice showed substantial weight gain, alleviated colitis severity, decreased inflammatory factors, and improved gut microbiota (GM) composition and bile acid conversion, suggesting SCH's potential as a UC treatment through the regulation of the SGK1/NLRP3 pathway and GM balance. This evidence concerns the gene NLRP3 and colitis.